Abstract
Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bangerter M, Moog F, Greisshammer M, Reske SN and Bergman L (1998) Role of whole body FDG-PET in predicting relapse in residual masses after treatment of lymphoma. Br J Haematol 102: 148
Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER Jr, Einhorn LH, Roth BJ and Donohue JP (1997) Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 50: 957–962
Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenkneckt GG, Jaske G and Buell U (1998) FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 39: 815–822
de Wit M, Bunmann D, Beyer W, Herbst K, Clausen M and Hossfeld DK (1997) Whole body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8: 57–60
Duchesne GM, Stenning SP, Aass N, Mead GM, Fossa SD and Oliver RTD (1997) Minimal benefit from radiotherapy after chemotherapy for metastatic seminoma: analysis of medical research council (MRC-UK) database. Proc ASCO 16: 318
Ganjoo KN, Chan RJ, Sharma M and Einhorn LH (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. JCO 17: 3457–3460
Javadpour N (1992) Current status of tumor markers in testicular cancer. A practical review. Eur Urol 21: 34–36
Kalofonos HP, Kosmas C, Pawlikowska TR, Bamias A, Snook D, Dhokia B, Sivolapenko GB and Courtenay-Luck NS (1990) Immunolocalisation of testicular tumours using radiolabelled monoclonal anitbody to placental alkaline phosphatase. J Nucl Med Allied Sci 34: 294–298
Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ and Smith MA (1999) A PET study of18FDG uptake in soft tissue masses. Eur J Nucl Med 26: 22–30
Mead GM (1995) Testis. In: Treatment of Cancer. 3rd edn, Price P, Sikora K (eds) pp 627–645. Chapman Hall: London
Mostofi FK, Spaander P, Grigor K, Parkinson CM, Skakkekaek NE and Oliver RTD Consensus on pathological classifications of testicular tumours. (1990) In: EORTC genitourinary group monograph 7. Prostate cancer and testicular cancer, pp 267–27; Wiley-Liss, New York
Muller-Mattheis V, Reinhardt M, Gerharz CD, Feurst G, Vosberg H, Meullwe-geartner HW and Ackermann R (1998) Positron emission tomography with [18F]-2-fluoro-2-deoxy-D-glucose in the diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe-Ausgabe A 37: 609–620
O'Doherty MJ, Barrington SF, Campbell M, Owen J and Barber CS (1997) PET scanning and the human immunodeficiency virus positive patient. J Nucl Med 38: 1575–1583
Rathmall AJ, Brand IR, Carey BM and Jones WG (1993) Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit. Clin Oncol R Coll Radiol 5: 34–38
Saunders CAB, Dussek J, O'Doherty MJ and Maisey MN (1999) An evaluation of 18F-FDG whole body PET imaging in the staging of lung cancer. Ann Thoracic Surg 67: 790–797
Stephens AW, Gonin R, Hutchins GD and Einhorn LH (1996) Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 14: 1637–1641
Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF and Wahl RL (1999) Germ cell tumour: differentiation of viable tumor, mature teratoma and necrotic tissue with FDG PET and kinetic modelling. Radiology 211: 249–256
Uchiyama M, Kantoff PW and Kaplan WD (1994) Gallium-67 citrate imaging extragonadal and gonadal seminomas: relationship to radiologic findings. J Nucl Med 35: 1624–1630
Warren GP (1995) Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. J Clin Oncol 13: 2784–2788
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hain, S., O'Doherty, M., Timothy, A. et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 83, 863–869 (2000). https://doi.org/10.1054/bjoc.2000.1389
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1389
Keywords
This article is cited by
-
Positronenemissionstomographie bei Keimzelltumoren des Mannes
Der Urologe (2019)
-
PET/CT for the diagnostic assessment of patients with testicular cancer
Clinical and Translational Imaging (2018)
-
Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases
Current Urology Reports (2018)
-
The present and future of serum diagnostic tests for testicular germ cell tumours
Nature Reviews Urology (2016)
-
FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment
Nuclear Medicine and Molecular Imaging (2015)